ITI-1001

· Immunomic Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ITI-1001, covering 2024-12-06 to 2024-12-06. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) [Phase 1]

See pricing